Literature DB >> 11266527

Hamartin and tuberin expression in human tissues.

M W Johnson1, C Kerfoot, T Bushnell, M Li, H V Vinters.   

Abstract

Tuberous sclerosis (TSC) is a bigenic autosomal dominant disease caused by mutations in one of two tumor-suppressor genes, TSC1 and TSC2, resulting in benign hamartomas and low grade neoplasms in multiple organs including brain, heart, kidney, and skin. We report the results of an immunohistochemical study of the expression of the TSC gene products, tuberin and hamartin, in multiple tissues obtained at autopsy from 12 non-TSC affected patients ranging in age from 20 weeks gestation to 8 years, and surgical specimens from some organs. Tuberin and hamartin are expressed and are colocalized in most tissues. Contrary to a previous report, immunostaining with our antisera detected hamartin in liver, small and large intestine, prostate, and testes. We did not detect significant developmental differences in tuberin or hamartin expression in comparable tissues from patients of different ages. Although tuberin and hamartin colocalize in most tissues and cell types, we provide data that hamartin is more abundantly expressed than tuberin in cells within some tissues including the distal nephron and a population of cells of the endocrine pancreas. These data support the hypothesis that hamartin and tuberin interact and may function together in many tissues where they are co-expressed, but also suggest that hamartin has a discrete and specialized function in certain cell types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266527     DOI: 10.1038/modpathol.3880286

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

Review 1.  Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.

Authors:  Mary B Connolly; Glenda Hendson; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2006-06-13       Impact factor: 1.475

Review 2.  The neurobiology of the tuberous sclerosis complex.

Authors:  Leah Marcotte; Peter B Crino
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 3.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

Review 4.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

Review 5.  Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 6.  Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.

Authors:  Stephen C Juvet; Francis X McCormack; David J Kwiatkowski; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-10       Impact factor: 6.914

Review 7.  Giant cells: contradiction to two-hit model of tuber formation?

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak
Journal:  Cell Mol Neurobiol       Date:  2006-08-09       Impact factor: 4.231

Review 8.  Molecular mechanisms of renal development.

Authors:  Chong Min Kim; Kenneth I Glassberg
Journal:  Curr Urol Rep       Date:  2003-04       Impact factor: 2.862

9.  Tuberous sclerosis complex and Myc coordinate the growth and division of Drosophila intestinal stem cells.

Authors:  Alla Amcheslavsky; Naoto Ito; Jin Jiang; Y Tony Ip
Journal:  J Cell Biol       Date:  2011-05-09       Impact factor: 10.539

Review 10.  Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes.

Authors:  Viera Kútna; Valerie B O'Leary; Ehren Newman; Cyril Hoschl; Saak V Ovsepian
Journal:  Neurotherapeutics       Date:  2021-01-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.